Press release
Chronic Myeloid Leukemia Pipeline: Driving Innovation with 25+ Pioneering Companies Advancing Groundbreaking Therapies
Chronic Myeloid Leukemia Pipeline
DelveInsight's "Chronic Myelocytic Leukemia Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the Chronic Myelocytic Leukemia market. The report covers disease insights, treatment guidelines, and a detailed pipeline assessment from preclinical to marketed stages. It includes drug mechanisms, clinical studies, regulatory progress, and key developments such as collaborations, mergers, funding, and designations.
For emerging Chronic Myelocytic Leukemia drugs, the Chronic Myelocytic Leukemia pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Key Takeaways from the Chronic Myelocytic Leukemia Pipeline Report
• DelveInsight's Chronic Myelocytic Leukemia Pipeline analysis depicts a robust space with 25+ active players working to develop 25+ pipeline drugs for Chronic Myelocytic Leukemia treatment.
• The leading Chronic Myelocytic Leukemia companies include Novartis Oncology, Servier, Eltrombopag, Immune-Onc Therapeutics, H3 Biomedicine, Chroma Therapeutics, Nerviano Medical Sciences, Astex Pharmaceuticals, Takeda Oncology, Argenx, Kura Oncology, Incyte Corporation, Genentech, Inc., Sensei Biotherapeutics, Pfizer, BioLite, Inc., Newave Pharmaceutical Inc., Ellipses Pharma, Eli Lilly and Company, Aprea Therapeutics, Treadwell Therapeutics, Prelude Therapeutics, Onconova Therapeutics, Immune Pharmaceuticals, Teva Pharmaceutical Industries, and others are evaluating their lead assets to improve the Chronic Myelocytic Leukemia treatment landscape.
• Key Chronic Myelocytic Leukemia pipeline therapies in various stages of development include Imatinib, Radotinib, Olverembatinib, Venetoclax, Sabatolimab, Enasidenib, and others.
• In January 2025, Handa Pharmaceuticals announced that its U.S. subsidiary, Handa Therapeutics, acquired PHYRAGO (dasatinib) tablets, an FDA-approved treatment for chronic myeloid leukemia developed by Nanocopoeia. PHYRAGOTM is the first dasatinib product that can be co-administered with gastric acid-reducing agents.
• In November 2024, the FDA approved a reformulated version of nilotinib (Danziten) for adults with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (CML) in the chronic phase, and for those with chronic or acute-phase disease resistant or intolerant to prior imatinib treatment.
• In October 2024, Novartis announced that the FDA granted accelerated approval for SCEMBLIX (asciminib) for adults with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase (Ph+ CML-CP).
Request a sample and discover the recent breakthroughs happening in the Chronic Myelocytic Leukemia pipeline landscape @ https://www.delveinsight.com/report-store/chronic-myelocytic-leukemia-cml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Chronic Myelocytic Leukemia Overview
Chronic Myelomonocytic Leukemia (CMML) is a rare type of leukemia characterized by an elevated number of monocytes in the blood and bone marrow. Although it includes "leukemia" in its name, the World Health Organization (WHO) classifies CMML as a mixed myelodysplastic/myeloproliferative neoplasm (MDS/MPN). This classification reflects the disease's dual characteristics-features of myelodysplastic syndromes (MDS), which impact normal blood cell production, and myeloproliferative neoplasms (MPN), where bone marrow stem cells produce excessive blood cells, including red cells, white cells, or platelets.
Find out more about Chronic Myelocytic Leukemia medication @ https://www.delveinsight.com/report-store/chronic-myelocytic-leukemia-cml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Chronic Myelocytic Leukemia Treatment Analysis: Drug Profile
Sabatolimab: Novartis Oncology
Sabatolimab (MBG 453) is a monoclonal antibody targeting T-cell immunoglobulin and mucin domain 3 (TIM-3), under development by Novartis Oncology. It is currently in Phase III clinical trials for the treatment of Chronic Myeloid Leukemia (CML).
Enasidenib: Servier
Enasidenib (AG 221) is an orally administered small molecule inhibitor of isocitrate dehydrogenase 2 (IDH2), developed by Servier. The drug is presently in Phase I clinical trials for the treatment of Chronic Myeloid Leukemia (CML).
Key Chronic Myelocytic Leukemia Therapies and Companies
• Imatinib: Novartis Pharmaceuticals
• Radotinib HCl: Il-Yang Pharm. Co., Ltd.
• Olverembatinib: Ascentage Pharma Group Inc.
• Venetoclax: AbbVie
• Sabatolimab: Novarits Oncology
• Enasidenib: Servier
Learn more about the novel and emerging Chronic Myelocytic Leukemia pipeline therapies @ https://www.delveinsight.com/report-store/chronic-myelocytic-leukemia-cml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Chronic Myelocytic Leukemia Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.
By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
By Route of Administration
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
By Molecule Type
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Scope of the Chronic Myelocytic Leukemia Pipeline Report
• Coverage: Global
• Key Chronic Myelocytic Leukemia Companies: Novartis Oncology, Servier, Eltrombopag, Immune-Onc Therapeutics, H3 Biomedicine, Chroma Therapeutics, Nerviano Medical Sciences, Astex Pharmaceuticals, Takeda Oncology, Argenx, Kura Oncology, Incyte Corporation, Genentech, Inc., Sensei Biotherapeutics, Pfizer, BioLite, Inc., Newave Pharmaceutical Inc., Ellipses Pharma, Eli Lilly and Company, Aprea Therapeutics, Treadwell Therapeutics, Prelude Therapeutics, Onconova Therapeutics, Immune Pharmaceuticals, Teva Pharmaceutical Industries, and others.
• Key Chronic Myelocytic Leukemia Pipeline Therapies: Imatinib, Radotinib, Olverembatinib, Venetoclax, Sabatolimab, Enasidenib, and others.
Dive deep into rich insights for drugs used for Chronic Myelocytic Leukemia treatment; visit @ https://www.delveinsight.com/report-store/chronic-myelocytic-leukemia-cml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Table of Contents
1. Introduction
2. Executive Summary
3. Chronic Myelocytic Leukemia Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Chronic Myelocytic Leukemia Pipeline Therapeutics
6. Chronic Myelocytic Leukemia Pipeline: Late-Stage Products (Phase III)
7. Chronic Myelocytic Leukemia Pipeline: Late-Stage Products (Phase III)
8. Chronic Myelocytic Leukemia Pipeline: Mid-Stage Products (Phase II)
9. Chronic Myelocytic Leukemia Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix
Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Chronic Myeloid Leukemia Pipeline: Driving Innovation with 25+ Pioneering Companies Advancing Groundbreaking Therapies here
News-ID: 3936870 • Views: …
More Releases from DelveInsight
Fuchs Dystrophy Pipeline Insight 2025: Emerging Cell and Gene Therapies Reshape …
DelveInsight's "Fuchs Dystrophy - Pipeline Insight, 2025" explores the dynamic pipeline for Fuchs Endothelial Corneal Dystrophy (FECD), a progressive eye disease characterized by corneal endothelial cell loss, leading to vision impairment and potential blindness. Current treatment relies on corneal transplantation, which is limited by donor shortages and surgical risks.
The pipeline showcases novel cell-based therapies, including endothelial cell injection and regenerative strategies designed to restore corneal transparency without the need for…
Polycystic 0vary Syndrome (PCOS) Pipeline Insight 2025: Innovative Hormonal and …
DelveInsight's "Polycystic 0vary Syndrome - Pipeline Insight, 2025" provides a thorough analysis of emerging therapeutic strategies for PCOS, a common endocrine disorder affecting reproductive-age women and associated with infertility, metabolic dysfunction, and psychological comorbidities. Current management relies heavily on lifestyle modification and symptom-targeted pharmacotherapy, leaving substantial unmet needs.
The pipeline features novel hormonal modulators, including selective androgen receptor antagonists, estrogen receptor modulators, and progesterone analogs, designed to restore hormonal balance…
Influenza A Virus H5N1 Subtype Pipeline Insight 2025: Next-Generation Vaccines a …
DelveInsight's "Influenza A Virus H5N1 Subtype - Pipeline Insight, 2025" presents a detailed overview of the therapeutic landscape for H5N1, a highly pathogenic avian influenza virus associated with severe respiratory disease and high mortality rates in humans. The pandemic potential of H5N1 continues to drive intense global R&D efforts.
The pipeline is rich with next-generation vaccines, including mRNA-based platforms, recombinant protein vaccines, and universal influenza vaccine candidates targeting conserved viral epitopes.…
Spasmodic Torticollis Pipeline Insight 2025: Novel Neurotoxins and Neuromodulati …
DelveInsight's "Spasmodic Torticollis - Pipeline Insight, 2025" provides a comprehensive analysis of the evolving treatment landscape for Spasmodic Torticollis (cervical dystonia), a chronic neurological disorder characterized by involuntary neck muscle contractions and abnormal head postures. Current standard therapies, including botulinum toxin injections, offer relief but remain limited by their variable duration of effect and the development of resistance.
The pipeline features next-generation botulinum toxin formulations, designed to extend therapeutic duration and…
More Releases for Chronic
Chronic Pain Treatment Market - Relieving Chronic Pain: Discover the Latest Inno …
Newark, New Castle, USA: The "Chronic Pain Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Chronic Pain Treatment Market: https://www.growthplusreports.com/report/chronic-pain-treatment-market/8030
This latest report researches the industry structure,…
Refractory Chronic Cough Therapeutics Market - Silencing the Cough: Innovative T …
Newark, New Castle, USA: The "Refractory Chronic Cough Therapeutics Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Refractory Chronic Cough Therapeutics Market: https://www.growthplusreports.com/report/refractory-chronic-cough-therapeutics-market/7991
This latest report researches the…
Chronic Pulmonary Aspergillosis Drugs Market - Revitalizing Lungs: Revolutionary …
Newark, New Castle, USA - new report, titled Chronic Pulmonary Aspergillosis Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Pulmonary Aspergillosis Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Pulmonary Aspergillosis Drugs market. The report offers…
Chronic Hepatitis Therapeutics Market - Empowering Liver Health, Defying Chronic …
Newark, New Castle, USA - new report, titled Chronic Hepatitis Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Hepatitis Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Hepatitis Therapeutics market. The report offers an overview of…
Chronic Phase Chronic Myeloid Leukemia Market to Witness Growth by 2032, Estimat …
DelveInsight's "Chronic Phase Chronic Myeloid Leukemia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Chronic Phase Chronic Myeloid Leukemia , historical and forecasted epidemiology as well as the Chronic Phase Chronic Myeloid Leukemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Chronic Phase Chronic Myeloid Leukemia market report provides current treatment practices, emerging drugs, the market share…
Boot chronic pain
For immediate release
Due to our rushed lives and stressful environment, many people are suffering from chronic pain and fatigue.
We feel permanently tired and are barely able to get through our normal day. One is able to change this status when following the guidelines the book "Tired of being Tired to the point of being Gatvol (Fed Up). Some people will need a team of medical practitioners to help them…
